TABLE 1.
Patient clinical and transplants characteristics
| Characteristics | HID group (N = 75) | MSD group (N = 81) | P value |
|---|---|---|---|
| Age, median (range) | 58.0 (50.4‐69.0) | 57.5 (50.5‐68.0) | .741 |
| Sex | .999 | ||
| Male | 51 (68.00%) | 56 (69.14%) | |
| Female | 24 (32.00%) | 25 (30.86%) | |
| Follow‐up in months, median (range) | 25.2 (0.4‐73.3) | 27.9 (2.1‐74.3) | .409 |
| Disease, N (%) | .845 | ||
| AML | 60 (80.0%) | 63 (77.8%) | |
| MDS | 15 (20.0%) | 18 (22.2%) | |
| Stem cell source N (%) | <.0001 | ||
| BM + PBSC | 75 (100%) | ||
| PBSC | 81 (100%) | ||
| AML in CR, N (%) | .999 | ||
| CR | 50 (83.3%) | 52 (82.5%) | |
| No CR | 10 (16.7%) | 11 (17.5%) | |
| Genetics risk of AML, N(%) | .858 | ||
| Favorable risk | 6 (10.0%) | 6 (9.5%) | |
| Intermediate risk | 8 (13.3%) | 9 (14.3%) | |
| Poor risk | 28 (46.7%) | 25 (39.7%) | |
| Not available | 18 (30.0%) | 23 (36.5%) | |
| Cytogenetics risk of MDS, N(%) | .719 | ||
| Very good | 0 | 0 | |
| Good | 0 | 0 | |
| Intermediate | 4 (26.7%) | 2 (11.1%) | |
| Poor | 2 (13.3%) | 3 (16.7%) | |
| Very poor | 3 (20.0%) | 4 (22.2%) | |
| Not available | 6 (40.0%) | 9 (50.0%) | |
| Donor age, median (range) | 26 (14‐49) | 49 (37‐63) | <.0001 |
| Sex mismatch, N (%) | .169 | ||
| Female donor/Male recipient | 19 (25.3%) | 29 (35.8%) | |
| Others(M/M,F/F,M/F) | 56 (74.7%) | 52 (64.2%) | |
| Relationship between donor and recipient, N (%) | <.0001 | ||
| Sibling | 20 (26.7%) | 81 (100%) | |
| Child | 55 (73.3%) | 0 | |
| HCT‐CI score | |||
| 0‐2 | 61 (81.3%) | 68 (84.0%) | .678 |
| ≥3 | 14 (18.7%) | 13 (16.0%) | |
| Mononucleated cell count (range, 108/kg) | 9.9 (3.5‐13.5) | 10.0 (5.9‐38.0) | .442 |
Abbreviations: AML, acute myeloid leukemia; BM, bone marrow; CR, complete remission; HCT‐CI, hematopoietic cell transplantation comorbidity index; HID, haploidentical related donor; MDS, myelodysplastic syndrome; MSD, matched sibling donor; PBSC, peripheral blood stem cell.